Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Cash (2016 - 2026)

Spyre Therapeutics' Change in Cash history spans 11 years, with the latest figure at $20.8 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 16.71% year-over-year to $20.8 million; the TTM value through Dec 2025 reached -$3.7 million, up 96.29%, while the annual FY2025 figure was -$3.7 million, 96.29% up from the prior year.
  • Change in Cash reached $20.8 million in Q4 2025 per SYRE's latest filing, up from -$16.8 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $200.1 million in Q2 2023 to a low of -$182.4 million in Q2 2024.
  • Average Change in Cash over 5 years is -$310800.0, with a median of -$189000.0 recorded in 2022.
  • Peak YoY movement for Change in Cash: tumbled 11737.94% in 2023, then surged 28116.06% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$9.5 million in 2021, then skyrocketed by 56.92% to -$4.1 million in 2022, then surged by 2472.4% to $97.3 million in 2023, then plummeted by 81.66% to $17.8 million in 2024, then grew by 16.71% to $20.8 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Change in Cash are $20.8 million (Q4 2025), -$16.8 million (Q3 2025), and $33.2 million (Q2 2025).